2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4207 Impact of total body irradiation intensity on post-transplant outcomes of adolescent and young adults patients with acute lymphoblastic leukemia

Neda Amirmokhtari, MD, Muhammad Kashif Amin, MD, MSc, FACP2, Suhib Fahmawi, MD3, Forat Lutfi, MD4, Muhammad Mushtaq, MD5
1 University of Kansas Medical Center, Kansas City, Kansas, United States
2 University of Kansas Medical Center, Kansas City, Kansas, United States
3 University of Kansas Medical Center, Kansas City, Kansas, United States
4 University of Kansas Medical Center, Kansas City, Kansas, United States
5 University of Kansas Medical Center, Kansas City, Kansas, United States

Introduction:? Allogeneic stem cell transplantation (allo-SCT)?continues to?be the?only potential curative therapy?for?a subset of Acute Lymphoblastic Leukemia (ALL) patients.?Adolescent and young adult (AYA), defined as ages 15-39,?ALL patients have worse outcomes in comparison to their?younger?counterparts.?Optimizing the conditioning regimen these patients receive can improve their outcomes. Currently, the ASH guideline committee for AYA ALL patients?suggest?myeloablative conditioning (MAC) with total-body irradiation?(TBI)?rather than chemotherapy alone.?However, the?optimal?TBI?dose?intensity is unknown.?Our study will evaluate?the impact of?TBI?dose?intensity?in AYA ALL patients who received?MAC?Fludarabine?(Flu)-TBI.? 

Methods:? A retrospective multicenter review of AYA patients with ALL who underwent allo-SCT with Flu-TBI conditioning was?completed using?the publicly available dataset?P-6144, Mehta et al.,?from the?Center for International Blood and Marrow Transplant (CIBMTR) registry?from 2013 and 2021.?TBI intensity?was?divided into two groups,?TBI dose > 800?cGy?(high-dose?TBI group)?and TBI dose?< 400?cGy?(low-dose?TBI group)?due to database constraints.?Overall survival (OS) and graft-versus-host-disease-free relapse-free survival (GRFS) were analyzed by?Kaplan–Meier method and Cox proportional hazards models. Transplant-related mortality (TRM), acute graft-versus-host-disease (aGVHD), and chronic GVHD?(cGHVD)?were evaluated as competing-risk endpoints using Fine Gray?sub-distribution?hazard models. Multivariable models adjusted for age, sex, Karnofsky performance status (KPS), graft source, and HCT-CI. All analyses were performed using SAS 9.4. Significance was set at a two-sided p-value <0.05.  

Results:? The analysis?ultimately included?90?patients,?with?67 patients in the?high-dose?TBI group and 23 in the low-dose?TBI group. The mean age of the high-dose TBI group was 27.0?years?(±6.0) and?25.4?years?(±6.8) in the low-dose TBI group (p=0.138). Both groups had similar percentage of male patients, 62.7% in the high-dose TBI group and 73.9% in the low-dose TBI group (p=0.328). A higher proportion of the low-dose TBI group had an HCT-CI score of 0 (69.6% vs 16.4%, p=0.0002), KPS?of?90-100% (87.0% vs 56.7%, p=0.005), and peripheral blood as graft source (100% vs 80.6%, p=0.022). More patients in the high-dose TBI group were Caucasian in comparison to the low-dose TBI group (59.7% vs 34.8%, p<0.0001). All patients received post-transplant?Cytoxan (PtCy)?based GVHD?prophylaxis.?? 

On univariable?analysis,?the?high-dose?TBI?group was associated with a significantly improved OS (median OS?not reached vs 11.7?months, p=0.010), and a trend toward improved GRFS (median GRFS 9.4?months?vs 4.0 months, p ≈0.05).?After multivariable?adjustment, the high-dose TBI group remained independently associated with significantly improved?OS?(HR 2.37,?95% CI 1.22-4.63,?p=0.011), and the effect on GRFS was borderline (HR 1.73, 95% CI 0.99-3.01, p=0.54).? 

The low-dose TBI group had a significantly higher incidence of grade II-IV aGVHD (56.5% vs 28.4%, p=0.008), grade III-IV aGVHD (30.4% vs 7.5%, p=0.004), and TRM (34.8% vs 9.0%, p=0.008). Similar incidence of cGVHD was seen with both groups, with 44.8% in the high-dose TBI group and 39.1% in the low-dose TBI group (p=0.22). On multivariable?analysis, similar findings were seen as univariable analysis. The?low-dose?TBI group?had significantly higher incidence of grade II-IV aGVHD (SHR?2.79, 95% CI 1.12-6.95?p=0.027) and grade III-IV?aGVHD?(SHR?5.17, 95% CI 1.13-23.62, p=0.034) and?TRM?(SHR?3.03, 95% CI 1.44-6.36, p=0.0034). No significant association was seen with TBI dosing and?cGVHD?(SHR?1.32, 95% CI 0.54-3.20, p=0.542).? 

Conclusion:? This multicenter study showed that higher intensity TBI dosing had an associated significant?improvement?in?OS,?and reduced rates of?grade II-IV aGVHD, grade III-IV?aGVHD, and TRM in AYA ALL patients?who underwent?allo-SCT. Our findings suggest the?need for?additional?studies to evaluate the impact TBI dosing has on outcomes of AYA ALL patients who undergo?allo-SCT and consideration of higher TBI dosing when it is clinically feasible.  

Neda Amirmokhtari, MD: No relevant conflicts of interest to declare.